121 reports of this reaction
1.7% of all ATAZANAVIR SULFATE reports
#9 most reported adverse reaction
PSYCHIATRIC DECOMPENSATION is the #9 most commonly reported adverse reaction for ATAZANAVIR SULFATE, manufactured by Aurobindo Pharma Limited. There are 121 FDA adverse event reports linking ATAZANAVIR SULFATE to PSYCHIATRIC DECOMPENSATION. This represents approximately 1.7% of all 6,992 adverse event reports for this drug.
Patients taking ATAZANAVIR SULFATE who experience psychiatric decompensation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSYCHIATRIC DECOMPENSATION is a less commonly reported adverse event for ATAZANAVIR SULFATE, but still significant enough to appear in the safety profile.
In addition to psychiatric decompensation, the following adverse reactions have been reported for ATAZANAVIR SULFATE:
PSYCHIATRIC DECOMPENSATION has been reported as an adverse event in 121 FDA reports for ATAZANAVIR SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSYCHIATRIC DECOMPENSATION accounts for approximately 1.7% of all adverse event reports for ATAZANAVIR SULFATE, making it a notable side effect.
If you experience psychiatric decompensation while taking ATAZANAVIR SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.